Skip to main content

Advertisement

Table 2 Mean specific to non-specific [123 I]β-CIT binding ratios (BP ND ) (mean ± SD) and SERT-to-DAT ratios

From: SERT-to-DAT ratios in early Parkinson’s disease do not correlate with the development of dyskinesias

Region of interest PDNDYS(n= 27) PDDYS(n= 23) P value
Striatum, whole 4.02 ± 0.30 4.16 ± 0.24 0.66
Striatum, most affected side 3.43 ± 0.31 3.59 ± 0.27 0.57
Caudate nucleus, whole 6.02 ± 0.30 6.33 ± 0.25 0.52
Caudate nucleus, most affected side 5.34 ± 0.34 5.73 ± 0.28 0.43
Putamen, whole 3.03 ± 0.32 3.00 ± 0.26 0.93
Putamen, most affected side 2.39 ± 0.33 2.43 ± 0.28 0.82
Midbrain 1.05 ± 0.40 1.14 ± 0.35 0.41
Midbrain/Putamen, whole 0.33 ± 0.32 0.35 ± 0.36 0.48
Midbrain/Putamen most affected side 0.42 ± 0.32 0.44 ± 0.38 0.67
Midbrain/Caudate, whole 0.17 ± 0.32 0.17 ± 0.32 0.88
Midbrain/Caudate, most affected side 0.19 ± 0.34 0.19 ± 0.37 0.97
Midbrain/Striatum, whole 0.25 ± 0.31 0.26 ± 0.34 0.75
Midbrain/Striatum, most affected side 0.29 ± 0.31 0.30 ± 0.38 0.87
  1. SERT serotonin transporter, DAT dopamine transporter, SD standard deviation, PD Parkinson’s disease, PD NDYS PD patients subgroup that did not develop dyskinesias, PD DYS PD patients subgroup that developed dyskinesias.